benign prostatic hyperplasia

Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
  • noun

Synonyms for benign prostatic hyperplasia

enlarged prostate


Related Words

References in periodicals archive ?
American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) 2010: American Urological Association Education and Research, Inc;.
Difficulty urinating isn't always a sign of benign prostatic hyperplasia (BPH).
Drugs that work through adrenergic receptors, such as Hytrin and Cardura, for benign prostatic hyperplasia and hypertension, and Flomax for benign prostatic hyperplasia, have been marketed successfully for a number of years.
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
In addition to this newly issued patent Synaptic has 17 additional applications pending on its alpha adrenergic receptor and benign prostatic hyperplasia technology.
A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
EUA Guidelines on benign prostatic hyperplasia (BPH).
With the ThermaStent, Endocare is positioning itself to provide the enormous benign prostatic hyperplasia patient population with a potential treatment technology which is anticipated to provide both temporary and long-term relief to the sufferer in one procedure.
Fore Pharma's latest report 'Global Benign Prostatic Hyperplasia Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Benign Prostatic Hyperplasia market.
The technology developed by PROCEPT BioRobotics has the potential to standardize benign prostatic hyperplasia surgery, reduce the level of complexity required to deliver safe and effective therapy and ultimately improve the quality of life for men suffering from benign prostatic hyperplasia.
com/research/x6l37d/randd_trends_beni) has announced the addition of the "R&D Trends: Benign Prostatic Hyperplasia - Small Pipeline which Lacks Promise" report to their offering.
GlobalData's analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.
Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2011', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline.
Epidemiology: Benign Prostatic Hyperplasia - Expected to continue growing as the male population ages
Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011" provides data on the Benign Prostatic Hyperplasia clinical trial scenario.
Full browser ?